Breast Cancer

, Volume 17, Issue 3, pp 212–217 | Cite as

Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients

  • Yasuaki Sagara
  • Shoichiro Kosha
  • Shinichi Baba
  • Fumiko Dokiya
  • Shugo Tamada
  • Yoshiaki Sagara
  • Yoshito Matsuyama
  • Yasuyo Ohi
  • Mitsutake Ando
  • Yoshiaki Rai
  • Yoshiatsu Sagara
  • Tsutomu Douchi
Original Article



Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported.


The study included 656 postmenopausal breast cancer patients receiving ANA as postoperative adjuvant therapy in our hospital. Adverse events during ANA therapy, such as musculoskeletal effects and cerebro- and cardiovascular accidents, were investigated over a 5-year period. The percentage changes in lumbar (L2-4) spine bone mineral density (BMD) were determined in 71 patients receiving ANA alone and 26 patients receiving bisphosphonate in combination with ANA for 7–24 months.


The follow-up period ranged from 6 to 60 months (median 23 months). Joint pain, the most common adverse event, was observed in 3.6% (24/656) of the patients. Cerebral infarctions occurred in 0.3% (2/656) of the patients, and no cardiovascular accidents occurred. Bone fractures occurred in nine patients receiving ANA alone. The mean age and BMD of the nine patients were 67.6 years and 71.8% (compared to the young adult mean BMD), respectively. Accumulated and annual fracture rates were 1.3 and 0.8%, respectively. A decrease in BMD was observed in 62.0% (44/71) of the ANA group compared to 26.9% (7/26) of the combination bisphosphonate group (P < 0.01).


Incidence of adverse events during AI therapy in this Japanese postmenopausal population appears to be lower than that of the ATAC trial. The incidence of bone fractures during AI therapy is lower in Japan, and the addition of bisphosphonates enhances bone health. We should perform a prospective trial in the future to investigate the precise risk of bone fractures in Japanese patients.


Breast cancer Aromatase inhibitor Anastrozole Bone mineral density Fracture 


  1. 1.
    McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007;43(17):2523–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Paterson AH. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer. 2005;5 Suppl(2):S41–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. Clin Breast Cancer. 2005;5(Suppl2):S63–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22):5126–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer. 2005;5(Suppl2):S35–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Coleman RE. Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology (Williston Park). 2004;18(5 Suppl 3):16–20.Google Scholar
  8. 8.
    Douchi T, Kosha S, Kan R, Nakamura S, Oki T, Nagata Y. Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents. Obstet Gynecol. 1997;90(1):12–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer. 2000;1 Suppl 1:S9–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997;3(7):1101–8.PubMedGoogle Scholar
  11. 11.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Buzdar AU. The ATAC (Arimidex, Tamoxifen, alone or in combination) trial: an update. Clin Breast Cancer. 2004;5(Suppl 1):S6–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol. 2006;33(2 Suppl 7):S13–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8(2):119–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008;112(3 Suppl):700–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. J Obstet Gynaecol Res. 2007;33(5):696–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Hadji P. Reducing the risk of bone loss associated with breast cancer treatment. Breast. 2007;16 (Suppl 3):S10–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol. 2004;31(6 Suppl 12):23–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Aapro MS. Long-term implications of bone loss in breast cancer. Breast. 2004;13 (Suppl 1):S29–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982;59(6):680–6.PubMedGoogle Scholar
  22. 22.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.CrossRefPubMedGoogle Scholar
  24. 24.
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang MC, Aguirre M, Bhudhikanok GS, Kendall CG, Kirsch S, Marcus R, et al. Bone mass and hip axis length in healthy Asian, black, Hispanic, and white American youths. J Bone Miner Res. 1997;12(11):1922–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20(2):185–94.CrossRefPubMedGoogle Scholar
  27. 27.
    Douchi T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Yamasaki H, et al. The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women. Maturitas. 2000;35(1):25–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat. 2007;105 (Suppl 1):75–89.CrossRefPubMedGoogle Scholar
  30. 30.
    Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277(19):1539–45.CrossRefPubMedGoogle Scholar
  31. 31.
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21(8):1215–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Scott LJ, Keam SJ. Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs. 2006;66(3):353–62.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Yasuaki Sagara
    • 1
  • Shoichiro Kosha
    • 3
  • Shinichi Baba
    • 1
  • Fumiko Dokiya
    • 1
  • Shugo Tamada
    • 1
  • Yoshiaki Sagara
    • 1
  • Yoshito Matsuyama
    • 1
  • Yasuyo Ohi
    • 2
  • Mitsutake Ando
    • 1
  • Yoshiaki Rai
    • 1
  • Yoshiatsu Sagara
    • 1
  • Tsutomu Douchi
    • 3
  1. 1.Department of Breast OncologySagara Hospital, Hakuaikai Medical CorporationKagoshimaJapan
  2. 2.Department of PathologySagara Hospital, Hakuaikai Medical CorporationKagoshimaJapan
  3. 3.Department of Obstetrics and Gynecology, Faculty of MedicineKagoshima UniversityKagoshimaJapan

Personalised recommendations